The consensus analyst price target for Senseonics Holdings has recently dropped sharply, declining from approximately $25.33 to $18.92 per share. This change reflects a shift in sentiment, as analysts weigh growth opportunities against rising commercial execution risks. Read on to learn how investors can continue tracking these evolving expectations for Senseonics in the months ahead.
Stay updated as the Fair Value for Senseonics Holdings shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Senseonics Holdings.
š Bullish Takeaways
-
Barclays initiated coverage on Senseonics with an Overweight rating and a $1.50 price target, citing the Eversense 365 implantable sensor system as a “new and important category” for people with diabetes who suffer fatigue. The firm anticipates significant demand growth beginning in the latter half of 2026.
-
TD Cowen maintained its Buy rating after the recent stock split and applied a sales multiple of 6.75 to 2028 sales estimates. The new $15 price target, down from $25, reflects continued recognition of Senseonics’s long-term commercial potential even as near-term execution risks are factored in with a higher discount rate.
-
Stifel resumed coverage with a Hold rating and a $9 price target, noting physician diligence “favorably” and highlighting Eversense 365’s growing market share, along with Gemini’s position as a leading CGM innovation.
š» Bearish Takeaways
-
Stifel flagged concerns about Senseonics soon taking commercial operations back from Ascensia and indicated this move will likely require additional capital. The analyst sees the Freedom sensor, expected in the latter half of 2027, as “the form factor that will matter most for physicians and patients,” implying near-term uncertainties remain.
-
TD Cowen’s substantial price target reduction from $25 to $15 underscores rising commercial execution risk and reinforces analysts’ caution around operational challenges impacting valuation.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
-
Senseonics Holdings has joined the NASDAQ Composite Index, increasing its visibility and access to a broader investor base.
-
The company will move its primary exchange listing from NYSE MKT LLC to Nasdaq Global Select, effective November 14, 2025. This change is aimed at aligning with industry peers and enhancing market appeal.
-
For 2025, Senseonics is projecting global net revenue of approximately $35 million and anticipates doubling its global patient base as enrollment for the Eversense 365 system continues to grow.
-
A 1-for-20 reverse stock split, which includes a proportional reduction in authorized shares, is scheduled to take effect on October 17, 2025.
-
To support its transition to in-house commercialization and distribution, Senseonics has secured a $100 million loan and security agreement. This provides additional capital for future investments and operations.